Did you know that, in addition to large molecule work, Altasciences' preclinical team has extensive experience in designing and conducting safety assessment programs for small molecules? Our solutions meet all regulatory requirements, and include IND/NDA-enabling toxicology, safety pharmacology, and laboratory services in both rodent and non-rodent species.

Choose Altasciences for your small molecule safety assessment program and let us guide you seamlessly through each milestone.

February is Heart Month, a time to raise awareness on cardiovascular health. Cardiac safety issues are one of the main reasons promising drugs are halted in development.

With the collaboration of a number of leading core ECG vendors and our in-house clinical units specially designed for assessing cardiac safety, Altasciences has designed and conducted over 30 early cardiac safety and QT prolongation studies.

Whether you choose to conduct your cardiac assessment trials earlier (such as in first-in-human studies) or a little later (after completing Phase II), you can benefit from the following advantages:

In this issue of The Altascientist, we discuss the ICH regulations, and provide a thorough review of the design and timing of QT studies for your drug development program.

Included is a recent case study on the QT assessment in a novel cannabis trial involving 80 subjects.

Renowned for our full-service offering, we often get asked — how does Altasciences manage the development process for biologics and biosimilars so seamlessly from the required preclinical studies to first-in-human trials?

With over 25+ years of extensive experience conducting clinical trials and strategic alliances with a number of leading research centers, ,Altasciences is the best partner for studies requiring access to a large database of patients with metabolic disorders.

We have completed over 50 studies to date. Our database of over 345,000 participants includes:

In a recent NASH study, Altasciences had the best recruitment numbers out of 10 global sites recruiting for the study, even though we were included in the recruitment process only two months after the other sites. When the overall objective was met and recruitment was stopped, we had recruited more than 30% of the patients.

We have much more to share, including a Q&A session on clinical trials for metabolic disorders with an expert in the field, our end-to-end recruitment process, and a case study on diabetes.

Read more